Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT06787053

Selecting Hypoxic Tumours for Treatment Modification

Selecting Hypoxic Tumours for Treatment Modification — Recruiting • Oncology • NCT06787053.

📅 12 May 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06787053
Sponsor
University of Manchester
Start
2024-10-16
ClinicaliQ Trial Snapshot
  • Selecting Hypoxic Tumours for Treatment Modification — Recruiting • Oncology • NCT06787053.
  • What is being tested: Methods to identify and select patients with hypoxic solid tumours for treatment intensification strategies, since hypoxic tumours demonstrate reduced radiotherapy responsiveness compared to normoxic tumours.
  • Patient eligibility overview: Solid tumour patients scheduled for radiotherapy, with particular focus on the >25% of this population with hypoxic tumours, who currently have poor treatment outcomes with standard radiotherapy alone.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Approximately 50% of cancer patients with solid tumours will be treated with radiotherapy. A significant proportion (>25%) of patients have hypoxic tumours which respond poorly to radiotherapy. Hypoxic tumours have a poor prognosis. This can be improved with treatment intensification. Treatment intensification can be modification with CON (breathing O2-enriched air + oral administration of nicotinamide), chemoradiosensitisation, radiation dose-escalation or additional systemic treatments, significantly improving response of the tumours to radiotherapy. However, there are currently no clinically approved biomarkers to identify hypoxic tumours. Our group has developed and validated gene-expression signature-based…

Eligibility Snapshot
  • : This will be tumour site dependent. Bladder: * Older than age 18 years. * Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner. * Able to give informed consent. Cervix: * Older than age 18 years. * Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner. * Able to give informed consent. Prostate: * Older than age 18 years. * Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner. * Able to give informed consent.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors
Oncology · 28 Apr 2026
Ripretinib is recommended as an option for adults with advanced gastrointestinal stromal tumours who have received 3 or more prior kinase inhibitors…
View guideline →
Guideline
Bladder Cancer: Diagnosis and Management (NICE NG2)
Oncology · 27 Mar 2026
Blue light cystoscopy with hexaminolevinate improves detection of recurrent bladder tumours compared to white light cystoscopy alone, particularly for carcinoma in situ.…
View guideline →
Guideline
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma
Oncology · 21 Apr 2026
Pembrolizumab is recommended as neoadjuvant treatment prior to surgery for resectable locally advanced head and neck squamous cell carcinoma, followed by adjuvant…
View guideline →
Guideline
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)
Oncology · 17 Mar 2026
I appreciate your request, but I need to be transparent: the content provided only includes the title, metadata, and editorial notes -…
View guideline →
Clinical Brief
‘Would I have made it to 60 if my cancer symptoms weren’t detected?’
Gastroenterology · BBC Health · 01 Apr 2026
I appreciate you sharing this article, but I'm unable to provide a meaningful summary as the content provided contains only a title…
View brief →
Clinical Brief
Ultrasound delays putting pregnant women and cancer patients at risk, sonographers say
Oncology · BBC Health · 28 Mar 2026
Ultrasound service capacity is insufficient due to inadequate sonographer training, creating delays that compromise care for pregnant women and cancer patients requiring…
View brief →